This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Medical University of Innsbruck, Oncotyrol-Center for Personalized Cancer Medicine Gmbh (Ltd.), Vichem Chemie Kutato Korlatolt Felelossegu Tarsasag. Active years: 2013-2021.
Company Filing History:
1 out of 12 
1 out of 1 
1 out of 1 Years Active: 2013-2021
Title: Lukas A Huber: Innovator in Pharmaceutical Chemistry
Introduction
Lukas A Huber is a notable inventor based in Schwaz, Austria. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target various diseases, including cancer. With a total of 2 patents, Huber's work exemplifies the intersection of innovation and medical science.
Latest Patents
One of Huber's latest patents is focused on 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin-dependent kinase inhibitors. This invention relates to compounds that are particularly useful in the prophylaxis and treatment of cancer and other proliferative diseases. The patent details processes for synthesizing these compounds and their intermediates, showcasing Huber's commitment to advancing medical therapies.
Another significant patent involves the medical and pharmaceutical use of substituted 1H-imidazo[4,5-c]quinolin-4-amines. This invention emphasizes the use of Imiquimod® and Gardiquimod® in combination with Akt inhibitors for treating haematological cancers, particularly multiple myeloma. Huber's innovative approach in this area highlights the potential for improved therapeutic strategies in oncology.
Career Highlights
Lukas A Huber has worked with esteemed institutions such as the Medical University of Innsbruck and Vichem Chemie Kutató Korlátolt Felelősségű Társaság. His experience in these organizations has allowed him to collaborate on groundbreaking research and development projects that have the potential to impact patient care significantly.
Collaborations
Throughout his career, Huber has collaborated with notable professionals, including János Pató and László Örfi. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of pharmaceutical research.
Conclusion
Lukas A Huber's contributions to pharmaceutical chemistry through his patents and collaborations demonstrate his dedication to advancing medical science. His work continues to inspire future innovations in the treatment of complex diseases.